Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 98,635 Shares

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) CFO Oluyemi Okupe sold 98,635 shares of Hims & Hers Health stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $21.42, for a total transaction of $2,112,761.70. Following the transaction, the chief financial officer now directly owns 146,839 shares in the company, valued at $3,145,291.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Oluyemi Okupe also recently made the following trade(s):

  • On Wednesday, March 20th, Oluyemi Okupe sold 9,912 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.82, for a total value of $156,807.84.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $21.62 on Tuesday. The firm’s 50-day simple moving average is $15.10 and its 200 day simple moving average is $12.16. The firm has a market cap of $4.64 billion, a P/E ratio of -2,161.50 and a beta of 1.08. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $22.10.

Hims & Hers Health (NYSE:HIMSGet Free Report) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.05) EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Piper Sandler boosted their price objective on Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, May 7th. Bank of America increased their price objective on shares of Hims & Hers Health from $17.25 to $22.00 and gave the stock a “buy” rating in a research report on Monday, June 3rd. Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. TheStreet upgraded Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Finally, Canaccord Genuity Group boosted their price target on Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Moderate Buy” and a consensus target price of $16.14.

Get Our Latest Report on Hims & Hers Health

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Cetera Advisors LLC acquired a new position in shares of Hims & Hers Health during the first quarter worth $396,000. Farallon Capital Management LLC increased its holdings in Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares in the last quarter. Virtu Financial LLC bought a new position in Hims & Hers Health in the first quarter valued at about $638,000. Strategic Wealth Partners Ltd. bought a new position in Hims & Hers Health in the first quarter valued at about $839,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Hims & Hers Health during the first quarter valued at about $1,770,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Read More

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.